Mavacamten + Placebo
Phase 3Completed 0 watching 0 views this week๐ Rising
69
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Obstructive Hypertrophic Cardiomyopathy
Conditions
Obstructive Hypertrophic Cardiomyopathy
Trial Timeline
Jan 4, 2022 โ Jul 22, 2024
NCT ID
NCT05174416About Mavacamten + Placebo
Mavacamten + Placebo is a phase 3 stage product being developed by LianBio for Obstructive Hypertrophic Cardiomyopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT05174416. Target conditions include Obstructive Hypertrophic Cardiomyopathy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05174416 | Phase 3 | Completed |
Competing Products
20 competing products in Obstructive Hypertrophic Cardiomyopathy